ProMIS™ Neurosciences, Inc. is at the forefront of developing innovative therapeutic solutions for neurodegenerative diseases through its proprietary technologies, ProMIS™ and Collective Coordinates. These computational discovery technologies enable the precise prediction and identification of toxic misfolded proteins that are central to the progression of various neurodegenerative disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), and Parkinson’s disease. By focusing on the toxic oligomers of amyloid-beta, ProMIS™ aims to create highly selective antibody therapies that target only the harmful forms of these proteins, thereby minimizing potential side effects associated with broader targeting strategies.

The company’s lead product candidate, PMN310, exemplifies this approach by selectively binding to toxic oligomers while avoiding interaction with non-toxic forms of amyloid-beta. This specificity is expected to result in a more favorable safety and efficacy profile compared to existing therapies. Additionally, ProMIS is exploring the development of a vaccine aimed at inducing an immune response against these toxic oligomers, potentially offering a preventative strategy for at-risk individuals. Through its commitment to precision medicine and a deep understanding of protein misfolding diseases, ProMIS Neurosciences is positioned to make significant advancements in the treatment of neurodegenerative conditions.

Canada

ProMIS Neurosciences is focused on the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy through the discovery and development of antibodies selective for toxic misfolded proteins driving these diseases.

ProMIS™ Neurosciences, Inc.

Company Details